{"aliases":[{"type":"USBrandName","name":"Nubeqa"},{"type":"CodeName","name":"ODM-201"},{"type":"CodeName","name":"BAY 1841788"},{"type":"CodeName","name":"BAY-1841788"},{"type":"CodeName","name":"BAY1841788"},{"type":"CodeName","name":"ODM 201"},{"type":"Synonym","name":"antiandrogen ODM-201"},{"type":"CASRegistryName","name":"1297538-32-9"}],"definition":{"html":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells.","text":"A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. Darolutamide binds to ARs in target tissues; subsequently, inhibiting androgen-induced receptor activation and facilitating the formation of inactive complexes that cannot translocate to the nucleus. This prevents binding to and transcription of AR-responsive genes that regulate prostate cancer cell proliferation. This ultimately leads to an inhibition of growth in AR-expressing prostate cancer cells."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/darolutamide","text":"Darolutamide"},"nciConceptId":"C104748","nciConceptName":"Darolutamide","termId":746231,"name":"darolutamide","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"darolutamide"}